Short Interest in Pluri Inc. (NASDAQ:PLUR) Expands By 22.7%

Pluri Inc. (NASDAQ:PLUR) was the recipient of a significant increase in short interest in January. As of January 30th, there was short interest totaling 22,147 shares, an increase of 22.7% from the January 15th total of 18,051 shares. Currently, 0.3% of the shares of the stock are sold short. Based on an average daily trading volume, of 10,055 shares, the short-interest ratio is currently 2.2 days. Based on an average daily trading volume, of 10,055 shares, the short-interest ratio is currently 2.2 days. Currently, 0.3% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pluri in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Pluri currently has a consensus rating of “Hold” and a consensus target price of $12.00.

Pluri Trading Up 4.2%

Pluri stock opened at $3.71 on Wednesday. The company has a market capitalization of $37.29 million, a P/E ratio of -0.75 and a beta of 0.67. The firm’s fifty day simple moving average is $3.27 and its 200-day simple moving average is $3.97. Pluri has a 1-year low of $2.82 and a 1-year high of $7.13.

Pluri (NASDAQ:PLUR) last released its earnings results on Thursday, February 12th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.06). The business had revenue of $0.20 million for the quarter, compared to analysts’ expectations of $0.64 million.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Pluri stock. Jane Street Group LLC purchased a new position in shares of Pluri Inc. (NASDAQ:PLUR) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 10,928 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned about 0.14% of Pluri as of its most recent SEC filing. Institutional investors and hedge funds own 16.59% of the company’s stock.

Pluri Company Profile

Pluri (NASDAQ:PLUR) is a clinical-stage biotechnology company focused on the development and manufacturing of placental-derived cell therapy products. The company’s proprietary three-dimensional microcarrier expansion platform enables large-scale, off-the-shelf production of PLX (placental expanded) cells, which are being investigated for a range of acute and chronic conditions. Pluri’s approach seeks to combine the regenerative and immunomodulatory properties of stromal cells with a scalable manufacturing process that does not require patient-specific cell harvesting.

Pluri advances its pipeline through internally funded research programs and strategic collaborations with academic institutions and government agencies.